<DOC>
	<DOCNO>NCT00615940</DOCNO>
	<brief_summary>This randomize , double-blind , placebo control phase II trial study well capecitabine work give combination WX-671 give alone treat patient receive first-line therapy her2negative metastatic breast cancer .</brief_summary>
	<brief_title>Combination Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy First-line Her2-negative Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Females age ≥ 18 year Patients appropriate palliative firstline , mono chemotherapy capecitabine Histological cytological confirm , noninflammatory metastatic breast cancer Availability paraffinembedded tumor tissue primary resection biopsy metastatic lesion . HER2negative breast cancer Complete stag within 2 week prior randomization ( 4 week bone scan ) . Radiologically confirmed disease ECOG performance status ≤ 2 Ability understand willingness voluntarily sign date write informed consent form screen Negative pregnancy test ( urine serum ) within 3 day first study drug woman childbearing potential . Use effective contraception study 3 month stop study drug treatment . Normal organ marrow function define laboratory parameter ( obtain within screen period ) within follow limit : neutrophil &gt; = 1.5 x 109/L ; platelet &gt; = 100 x 109/L ; hemoglobin &gt; = 9.0 g/dL ( 5.6 mmol/L ) . total bilirubin &lt; = 1.5 x upper limit normal ( ULN ) ; aspartate aminotransferase ( AST ) /ALT &lt; = 2.5 x ULN ( &lt; 5.0 x ULN patient liver metastasis ) ; serum creatinine &lt; = 2 x ULN , calculate creatinine clearance &gt; 45 mL/min accord Cockroft Gault formula ) . Endocrine therapy complete within 2 week start treatment ( i.e . previous hormone therapy allow provide washout period 2 week ) . Prior chemotherapy biologic therapy metastatic disease . Major surgery within 4 week prior start treatment . Other anticancer treatment ( e.g . hormone ) within 2 week start treatment . Treatment within 12 month adjuvant 5FU contain chemotherapy ( regarded indicating 5FU resistance ) and/or prior capecitabine therapy . Radiation therapy . Palliative radiation stable , nontarget lesion 2 week start treatment allow , provide patient recovered radiation sideeffects . History radiological evidence brain metastasis include previously treat , resect asymptomatic brain lesion leptomeningeal involvement . Active seizure disorder history cerebrovascular accident ( CVA ) transient ischemic ( TI ) attack within past 12 month . History malignancy within last 3 year except surgically cure nonmelanoma skin cancer cervical carcinoma situ . Active cardiac disease e.g . unstable angina , congestive heart failure , myocardial infarction ( MI ) within precede 6 month . Any medical condition prohibit standard imaging procedure Pregnant breastfeed . Any unrelated illness , e.g . active infection require parenteral antibiotic , inflammation , medical condition laboratory abnormality , judgment investigator might significantly affect patient ' study participation . Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion either study drug . Known hepatitis B/C HIV ( human immunodeficiency virus ) infection .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>HER2negative</keyword>
</DOC>